For Immediate Release
Invitrogen Corporation, BioTek Instruments, Inc. Announce Strategic Collaboration
Carlsbad, Calif., and Winooski, Vt., June 16, 2008 - Invitrogen Corporation, a provider of
essential life science technologies for research, production and diagnostics, and BioTek
Instruments, Inc., a leader in microplate instrumentation technology, have entered into a
collaboration agreement to validate the compatibility of Invitrogen’s reagents and technology
platforms with BioTek’s microplate detection instruments.
Invitrogen’s drug discovery products used to study key target classes have been validated on
BioTek’s Synergy™ 4 Multi-Mode Microplate Reader with Hybrid Technology™. This
includes:
 GeneBLAzer® FRET cell-based technology for signal transduction pathways and G
protein-coupled receptors,
 LanthaScreen™ TR-FRET technology for kinases and nuclear hormone receptors,
 Adapta™ Universal Kinase Assay, a new TR-FRET assay system for lipid kinases,
 Z’-LYTE® assay for kinase profiling,
 Omnia® assay for measuring real-time kinase activity.
Additionally, BioTek’s Synergy 4 and Synergy 2 Multi-Mode Microplate Readers have
received the LanthaScreen™ Certified+ designation from Invitrogen. Through this
collaboration, BioTek and Invitrogen will continue to develop and promote joint applications
for the drug discovery market.
“Through this partnership, drug discovery researchers will be able to obtain integrated
instrumentation and reagent solutions, thereby removing the frustration of discovering that
the biological assay system they have chosen is not compatible with the instrumentation and
vice versa,” said John Printen, director of Invitrogen’s Cell Signaling business segment. “The
pharmaceutical research scientist is increasingly under pressure to complete projects faster
and this partnership is designed to save the customer valuable time and resources.”
“Each company has a respective strength; and BioTek’s expertise in microplate technology
matches perfectly with Invitrogen’s advanced assay platforms,” said Gary Barush, Director of
Marketing and Sales for BioTek Instruments. “This partnership enables us to offer superior
support beyond that of our instruments, gain a better understanding of customer needs, and
partner with them to problem-solve drug discovery applications.”
About Invitrogen
Invitrogen Corporation (NASDAQ:IVGN) provides products and services that support
academic and government research institutions and pharmaceutical and biotech companies
worldwide in their efforts to improve the human condition. The company provides essential
life science technologies for disease research, drug discovery, and commercial bioproduction.
Invitrogen’s own research and development efforts are focused on breakthrough innovation
in all major areas of biological discovery including functional genomics, proteomics, stem
cells, cell therapy and cell biology -- placing Invitrogen’s products in nearly every major
laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California,
and conducts business in more than 70 countries around the world. The company employs
approximately 4,700 scientists and other professionals and had revenues of approximately
$1.3 billion in 2007. For more information, visit www.invitrogen.com.
About BioTek Instruments, Inc.
BioTek Instruments, Inc., headquartered in Winooski, VT, is a worldwide leader in the
design, manufacture, and sale of microplate instrumentation and software. The BioTek
Instruments, Inc. instrumentation is used to accelerate the drug discovery process, to advance
discoveries in genomics and proteomics, and to aid in the advancement of life science
research. Founded in 1968, BioTek Instruments is celebrating its 40th anniversary this year.
Safe Harbor Statement
Certain statements contained in this press release are considered “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and
it is Invitrogen’s intent that such statements be protected by the safe harbor created thereby.
Forward-looking statements include, but are not limited to; 1) BioTek and Invitrogen will
continue to develop and promote joint applications for the drug discovery market, 2) drug
discovery researchers will be able to obtain integrated instrumentation and reagent solutions.
Potential risks and uncertainties include, but are not limited to; the risks that the market will
not accept the companies’ products and services, or that the companies will be unsuccessful
in their efforts to develop new products and services, as well as other risks and uncertainties
detailed from time to time in Invitrogen’s Securities and Exchange Commission filings.
Synergy and Hybrid Technology are trademarks of BioTek Instruments. Adapta and
LanthaScreen are trademarks, and GeneBLAzer, Omnia and Z’-LYTE are registered
trademarks of Invitrogen Corporation.
Media Contacts
Invitrogen Corporation, Revelle Bailey, (760) 268-7482, revelle.bailey@invitrogen.com
BioTek Instruments, Inc., Xavier Amouretti, Product Manager, (802) 655-4040,
amourettix@biotek.com
Shaw & Todd Advertising and Marketing Communications, Chere Griffin, Account
Executive, (908) 668-1106 x15, cgriffin@shawtodd.com
##End##